Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528243 | 0.89 | L3MBTL1 (0.38) | L3MBTL1ADRB3ALDH1A1MAPTLMNA | |
| SCHEMBL2529782 | 0.87 | L3MBTL1 (0.35) | L3MBTL1ADRB3ALDH1A1MAPTLMNA | |
| SCHEMBL2528949 | 0.85 | L3MBTL1 (0.42) | L3MBTL1ADRB3ALDH1A1MAPTPPARG | |
| SCHEMBL2531906 | 0.84 | ADRB3 (0.38) | L3MBTL1ADRB3MAPTPPARGPPARA | |
| SCHEMBL2526478 | 0.84 | PPARG (0.38) | L3MBTL1ADRB3PPARGPPARA | |
| SCHEMBL2529154 | 0.83 | MAPK1 (0.40) | ADRB3ALDH1A1MAPTLMNACYP3A4 | |
| SCHEMBL2529623 | 0.82 | ADRB3 (0.45) | ADRB3PPARGPPARAHPGDADRB2 | |
| SCHEMBL2529261 | 0.81 | TDP1 (0.40) | L3MBTL1ADRB3ALDH1A1MAPTLMNA | |
| SCHEMBL2527546 | 0.81 | TDP1 (0.47) | L3MBTL1ADRB3ALDH1A1MAPTPPARG | |
| SCHEMBL2527446 | 0.81 | PPARG (0.42) | ADRB3PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039501-B2 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2011-10-18 | — | — | US | disclosed |
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | HRH1, HRH3, HRH2 | L3MBTL1 4486/4885ADRB3 557/4885ALDH1A1 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.